| Rimonabant (Acomplia) | Sanofi-Aventis | CB1 receptor antagonist | Under FDA review | Nausea, dizziness, diarrhea, joint pain Side effects |
| ATL-962 (Cetilistat) | Alizyme | Blocks fat absorption in the gut | Phase 3 to begin in 2006 | Some gastrointestinal side effects |
| AOD9604 | Metabolic Pharmaceuticals | Human growth hormone fragment that promotes fat-burning | Phase 2b | Some gastrointestinal effects at high doses |
| APD356 | Arena | Selectively stimulates sero-tonin receptor in hypothala-mus, decreasing appetite | Phase 2b | Nausea, headache |
| CP-946,598 | Pfizer | CB1 receptor antagonist | Phase 2 | Similar to other CB1 antagonists |
| PYY3-36 | Nastech Pharmaceuticals/Merck | Synthetic form of the appetite-suppressing hormone PYY | Phase 1 | Nausea, headache, dizziness |
| SLV-319 | Solvay Pharmaceuticals, Bristol-Myers Squibb | CB1 receptor antagonist | Phase 1 | Undisclosed |
 |
|
|
Sources: IMS Health, Decision Resources
|
